243 related articles for article (PubMed ID: 35235785)
1. SDHB knockout and succinate accumulation are insufficient for tumorigenesis but dual SDHB/NF1 loss yields SDHx-like pheochromocytomas.
Armstrong N; Storey CM; Noll SE; Margulis K; Soe MH; Xu H; Yeh B; Fishbein L; Kebebew E; Howitt BE; Zare RN; Sage J; Annes JP
Cell Rep; 2022 Mar; 38(9):110453. PubMed ID: 35235785
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
[TBL] [Abstract][Full Text] [Related]
3. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas.
Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Valdés N; Astudillo A; Balbín M; Pitiot AS; Jiménez-Fonseca P; Scola B; Tena I; Molina-Garrido MJ; Sevilla MA; Beristein E; Forga L; Villabona C; Oriola J; Halperin I; Suarez C; Chiara MD
Head Neck; 2019 Jan; 41(1):79-91. PubMed ID: 30549360
[TBL] [Abstract][Full Text] [Related]
5. Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit.
Bancel LP; Masso V; Dessein AF; Aubert S; Leteurtre E; Coppin L; Odou MF; Cao CD; Cardot-Bauters C; Pigny P
J Clin Endocrinol Metab; 2023 Aug; 108(9):2343-2352. PubMed ID: 36848172
[TBL] [Abstract][Full Text] [Related]
6. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
[TBL] [Abstract][Full Text] [Related]
7. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
[TBL] [Abstract][Full Text] [Related]
8. In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma.
Lussey-Lepoutre C; Bellucci A; Morin A; Buffet A; Amar L; Janin M; Ottolenghi C; Zinzindohoué F; Autret G; Burnichon N; Robidel E; Banting B; Fontaine S; Cuenod CA; Benit P; Rustin P; Halimi P; Fournier L; Gimenez-Roqueplo AP; Favier J; Tavitian B
Clin Cancer Res; 2016 Mar; 22(5):1120-9. PubMed ID: 26490314
[TBL] [Abstract][Full Text] [Related]
9. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
[TBL] [Abstract][Full Text] [Related]
10. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes.
Udager AM; Magers MJ; Goerke DM; Vinco ML; Siddiqui J; Cao X; Lucas DR; Myers JL; Chinnaiyan AM; McHugh JB; Giordano TJ; Else T; Mehra R
Hum Pathol; 2018 Jan; 71():47-54. PubMed ID: 29079178
[TBL] [Abstract][Full Text] [Related]
11. The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma.
Wang Y; Liu B; Li F; Zhang Y; Gao X; Wang Y; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1274239. PubMed ID: 37867526
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
13. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
14. From Nf1 to Sdhb knockout: Successes and failures in the quest for animal models of pheochromocytoma.
Lepoutre-Lussey C; Thibault C; Buffet A; Morin A; Badoual C; Bénit P; Rustin P; Ottolenghi C; Janin M; Castro-Vega LJ; Trapman J; Gimenez-Roqueplo AP; Favier J
Mol Cell Endocrinol; 2016 Feb; 421():40-8. PubMed ID: 26123588
[TBL] [Abstract][Full Text] [Related]
15. Succinate Mediates Tumorigenic Effects
Matlac DM; Hadrava Vanova K; Bechmann N; Richter S; Folberth J; Ghayee HK; Ge GB; Abunimer L; Wesley R; Aherrahrou R; Dona M; Martínez-Montes ÁM; Calsina B; Merino MJ; Schwaninger M; Deen PMT; Zhuang Z; Neuzil J; Pacak K; Lehnert H; Fliedner SMJ
Front Endocrinol (Lausanne); 2021; 12():589451. PubMed ID: 33776908
[TBL] [Abstract][Full Text] [Related]
16. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.
Rai SK; Bril F; Hatch HM; Xu Y; Shelton L; Kalavalapalli S; Click A; Lee D; Beecher C; Kirby A; Kong K; Trevino J; Jha A; Jatav S; Kriti K; Luthra S; Garrett TJ; Guingab-Cagmat J; Plant D; Bose P; Cusi K; Hromas RA; Tischler AS; Powers JF; Gupta P; Bibb J; Beuschlein F; Robledo M; Calsina B; Timmers H; Taieb D; Kroiss M; Richter S; Langton K; Eisenhofer G; Bergeron R; Pacak K; Tevosian SG; Ghayee HK
Metabolism; 2020 Sep; 110():154297. PubMed ID: 32562798
[TBL] [Abstract][Full Text] [Related]
17. The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors.
Xekouki P; Brennand A; Whitelaw B; Pacak K; Stratakis CA
Horm Metab Res; 2019 Jul; 51(7):419-436. PubMed ID: 30273935
[TBL] [Abstract][Full Text] [Related]
18. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
[TBL] [Abstract][Full Text] [Related]
19. Primary fibroblast co-culture stimulates growth and metabolism in Sdhb-impaired mouse pheochromocytoma MTT cells.
Richter S; D'Antongiovanni V; Martinelli S; Bechmann N; Riverso M; Poitz DM; Pacak K; Eisenhofer G; Mannelli M; Rapizzi E
Cell Tissue Res; 2018 Dec; 374(3):473-485. PubMed ID: 30159755
[TBL] [Abstract][Full Text] [Related]
20. Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma.
Rao JU; Engelke UF; Rodenburg RJ; Wevers RA; Pacak K; Eisenhofer G; Qin N; Kusters B; Goudswaard AG; Lenders JW; Hermus AR; Mensenkamp AR; Kunst HP; Sweep FC; Timmers HJ
Clin Cancer Res; 2013 Jul; 19(14):3787-95. PubMed ID: 23723300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
